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Abstract (250) 
Aim  
The aim of this systematic review and meta-analysis was to evaluate the effect of 
carbohydrate restriction on glycaemic control in Type 2 DM. 
Methods 
We searched Medline, EMBASE, & CINAHL from 1976 to April 2018. We included 
randomised controlled trials (RCTs) which restricted the quantity of carbohydrate compared 
to a control diet that aimed to maintain or increase carbohydrate, reported HbA1c as an 
outcome and reported the amount of carbohydrate consumed during or at the end of the 
study, with outcomes reported at 3 months or longer. 
Results 
We identified 1,402 studies. Twenty-five RCTs met inclusion criteria, incorporating 2,132 
participants for the main outcome. Definitions of low carbohydrate varied in studies. The 
pooled effect estimate from meta-analysis was WMD -0.09% (95% CI -0.28%, 0.10%) P = 
0.34, I2 80%, P <0.001 suggesting no effect from restricting the quantity of carbohydrate on 
HbA1c. Sub group analysis of diets containing 50-130g of carbohydrate resulted in a pooled 
effect estimate of -0.49% (-0.75, -0.23) P <0.001, I2 0%, P = 0.56 suggesting a clinically and 
statistically significant effect on HbA1c in favour of low CHO diets in studies of 6 months or 
less in duration. 
Conclusions 
There was no overall pooled effect on HbA1c in favour of restricting carbohydrate, however 
restriction of carbohydrate to 50-130g per day has beneficial effects on HbA1c in trials up to 
6 months. Future RCTs should be >12months, assess pre-study carbohydrate intake, use 
recognised definitions of low carbohydrate diets and examine reasons for non-concordance 
in greater detail.  
Source of funding: NIHR CDRF-2014-05-30. (PROSPERO: CRD42015023586) 
 
 
 
 
 
 Novelty Statement 
• A large number of trials and systematic reviews in this field show conflicting results 
for the effect of restricting carbohydrate on glycaemic control. 
• This study includes analysis of trials reporting adherence to the study diet, showing 
this has no material impact on the outcome, and brings the evidence up to date by 
including more recent trials.  
• Clinicians should inform patients with Type 2 DM there are a number of effective 
dietary approaches for improving glycaemic control, which may include restricting 
carbohydrate to 50-130g per day. 
 
Introduction 
Diabetes affects an estimated 4.5 million people in the UK and 415 million globally, with 
Type 2 DM accounting for approximately 90% of cases.1,2 In the United Kingdom Prospective 
Diabetes Study (UKPDS), each 11mmol/mol (1%) reduction in HbA1c was associated with a 
21% risk reduction for any end point and 37% for macrovascular complications.3 Nutrition 
therapy interventions have been shown to reduce HbA1c by up to 22mmol/mol (2.0%) and 
there is significant current interest in the role of dietary carbohydrates for weight control, 
and in the context of Type 2 DM for the control of glycaemia.4,5 However, the ideal amount 
of dietary carbohydrate remains unclear. Current American & European diabetes 
organisations do not make strong recommendations about the quantity of carbohydrate 
and rather state that monitoring of total carbohydrate is a key strategy in achieving 
glycaemic control, with the focus for dietary change instead targeted at weight loss in the 
overweight.6–8 The average proportion of energy from carbohydrate in the UK general 
population is 47%, and it is estimated a similar amount is consumed in people with Type 2 
DM.9  
 
Several reviews considering the binary options of low- or high-carbohydrate diets have 
produced mixed results, likely due to methodological differences and poor dietary 
adherence in included trials.10–13 Recent meta-analyses of low carbohydrate diets have 
consistently found a small but significant reduction in HbA1c in the pooled effect at 6 
months that was no longer present at 12 months, supporting the conclusions made in 
earlier reviews.13–15  Another recent review found modest reductions in HbA1c present at 12 
months.16 Research by van Wyk et al10 highlighted the difficulty people find in adhering to 
prescribed diets, showing just an 8g per day difference in the carbohydrate content of diets 
between study arms at the end of the studies. Recent reviews have acknowledged the issue 
of adherence, but none have performed sub-group analyses on trials demonstrating dietary 
adherence to establish the impact of this on the primary outcome. The search period of the 
most recent review of carbohydrate in Type 2 DM does not included the latest RCTs 
published.17 There is also an increasing interest in the use and effectiveness of dietary 
carbohydrate restriction for managing diabetes and weight. These factors underline the 
need for a good quality synthesis of the evidence in this area. Therefore, the aim of this 
review is to provide an updated evaluation the impact of carbohydrate restriction on 
glycaemic control in adults with Type 2 DM including the most recently published research 
and with an additional focus on trials demonstrating dietary adherence. 
 
Methods 
Data Sources and Searches  
This systematic review and meta-analysis was conducted with reference to the Cochrane 
Handbook for Systematic Reviews of Interventions18 and reported in accordance with the 
PRISMA statement.19 A protocol was published and registered with PROSPERO in advance.20  
The search dates were restricted to 1976 onwards (due to the introduction of HbA1c at this 
time 21) and were up to April 2018. Databases searched included Medline (1976 – April 
2018), Embase (1980 – April 2018) and CINAHL (1982 – April 2018). Databases of on-going 
trials, The Cochrane Library and DARE, dissertations and theses and other grey literature 
were also searched. Search terms and the search strategy were developed by the research 
team and search results were independently reviewed by PDM & SKR. Summary data were 
sought and data extraction carried out by PDM, verified by SKR, with any conflicts over 
inclusion resolved by discussion.  
 
Study Selection 
Studies were eligible for inclusion if they were randomized controlled trials (RCTs) including 
adults diagnosed with Type 2 DM; had a minimum intervention duration of 8 weeks and 
outcomes reporting at a minimum of 12 weeks; and the intervention restricted the 
proportion or quantity of dietary carbohydrate. Studies using active control diets were 
included, however not if the control diet included carbohydrate restriction in comparison to 
the intervention diet. Studies were not grouped according to the type of control diet and all 
forms of control diet that did not include a carbohydrate restriction were permitted, 
including low fat, high carbohydrate, low glycaemic index, high protein, Mediterranean and 
‘healthy eating’. Included studies also needed to report actual (self-reported or measured) 
carbohydrate intake during or at the end of the intervention and HbA1c as an outcome 
measure. All countries, languages and settings were eligible.  
 
Data Extraction and Quality Assessment 
Data extraction was carried out by PDM, verified by SKR, with any conflicts over inclusion 
resolved by discussion. Data were extracted to a purposely designed spread sheet by PDM 
and checked by SKR. Data items included: study and participant characteristics (including 
duration, setting, ethnicity, age, sex); details of the intervention & control diets (including 
macronutrient composition prescribed, other dietary advice given); outcome data for 
HbA1c, weight, blood pressure (BP) and lipids; and details of retention rates and dietary 
adherence, where available. Risk of bias was assessed according to the Cochrane Handbook 
for Systematic Reviews of Interventions18 at study level and inputted into Review Manager 
5.3.22 
 
Data Synthesis and Analysis 
Means and Standard Deviations (or Standard Error) were used to conduct meta-analyses for 
the primary outcomes HbA1c and body weight using a random effects model and to 
compare interventions using weighted mean difference and 95% confidence intervals. 
Where data for people with diabetes was part of a larger cohort including non-diabetes 
participants, if separate data were not reported, authors were contacted to request the 
relevant values for only the participants with Type 2 DM. Additional or missing data were 
obtained from 4 of the 5 authors contacted 23–26 and where they were not available, the 
study was not included in the meta-analysis. Data for the overall meta-analyses were taken 
from the longest available time point for each included study. Two studies did not report 
data for body weight and were therefore excluded from the meta-analysis.26,27 Comparison 
of the carbohydrate quantity of intervention diets was in absolute grams of carbohydrate, 
rather than % of total energy, to allow for direct and accurate comparison. Where studies 
reported only % of total energy from carbohydrate, a conversion was made using 4kcal per 
1g carbohydrate, based on the mean reported energy (calorie) intake for each study, or 
based on an estimated calorie intake of 2,000kcal if these data were not available.28 This 
level of calorie intake has been used by other researchers for conversion to grams of 
carbohydrate15,29 and is similar or greater than the amounts reported in trials included in 
this review (Table 1).  Included studies reported HbA1c values as DCCT-aligned (%)30 rather 
than the newer IFCC-standardised  concentrations31 and these were used in this review 
without conversion to avoid potential errors. Heterogeneity in the sample of studies was 
assessed using the I2 statistic and the significance of the associated Chi2 value (p<0.05). 
 
Sub-group Analysis 
Sub-group analysis based on levels of carbohydrate intake were conducted to elicit 
differences in the key outcomes between groups of carbohydrate intake. Level descriptors 
of carbohydrate intake proposed by Feinman and Acurso29 have been widely adopted in the 
field of carbohydrate research and were used to define the sub-groups in this meta-analysis. 
Only two studies32,33 met the definition of ‘High’ carbohydrate and therefore this group was 
collapsed with the ‘Moderate’ category to form a group named ‘Moderate+’ in this analysis. 
A further sub-group analysis was undertaken to achieve a key aim of this study, by 
conducting a meta-analysis of a subset of included studies demonstrating dietary 
adherence. Adherence to the study diet was defined for this purpose as +/- 10% of the 
prescribed carbohydrate (g) in the restricted carbohydrate group.  Heterogeneity within 
each subgroup was examined as well as the overall I2, and a test for heterogeneity between 
subgroups was also performed. 
 
Results  
Search Results 
The selection of studies is indicated in Figure 1 according to the PRISMA19 flow diagram. 
Initial database searches yielded 1,402 articles and 72 full-text articles were retrieved 
before eligibility could be established. There were 25 studies that met the inclusion criteria. 
 
Study Characteristics and risk of bias  
Characteristics of the 25 included trials are summarized in Table 1, grouped according to 
dietary intervention using the definitions of levels of carbohydrate prescribed and outlined 
in Table 2. The moderate and high carbohydrate categories were collapsed for the purpose 
of analyses as there were only two studies meeting the definition of high carbohydrate.  
 
The publication period covered 36 years and ranged from 1981 to 2017. Study duration 
ranged from 12 to 208 weeks, with a mean duration of 56 weeks. The majority of studies 
lasted longer than 26 weeks with 7 studies longer than 52 weeks. All except one study in the 
Low Carbohydrate category lasted for 26 weeks or less and, although this study was 104 
weeks duration, it only reported outcomes at 26 weeks.34 Study sample sizes ranged from 
1223 to 41935 and a total of 2,132 participants were included in this review. Of the 25 
included studies, 10 of the dietary interventions met the definition of ‘moderate 
carbohydrate’ (n= 1,111).  
 
Figures 2 and 3 (figure 3 available as supplementary material) show the risk of bias across 
all studies. The principal risk of bias stemmed from either the poor description of the 
randomization sequence and allocation concealment, or because there was no description 
of the pre-study dietary intake of participants (‘Other bias’). This represented more than 
one third of studies included in this review. 
 
Glycaemic Control  
The baseline and post-intervention values of HbA1c, weight, total cholesterol and BP are 
shown in (Tables 3 and 3a – supplementary material). Blood pressure and lipids were not 
routinely included as outcomes or reported in studies included and were not the main focus 
of this review.  
 
Significant between-group differences in HbA1c were observed in just 6 of the 25 trials. 36–41 
Some studies reported significant differences at 6 months which were not maintained at 12 
months and beyond.34,42 Meta-analyses conducted for HbA1c for all studies found no overall 
effect of modifying carbohydrate and demonstrated a high level of heterogeneity (WMD -
0.09%, 95% CI -0.28%, 0.10%, P = 0.34, I2 80%, P <0.001) (Figure 2). Sub-group analysis of 
studies meeting the definition of ‘very low carbohydrate’ (<50g per day) also found no 
overall effect with very low levels of heterogeneity observed (WMD -0.20%, 95% CI -0.42%, 
0.03%, P = 0.23, I2 25%, P = 0.09). Analysis of the sub group of 5 low carbohydrate diet 
studies (50-130g per day) showed a statistically and clinically significant result in favour of 
the intervention diet (WMD -0.48%, 95% CI -0.74%, -0.23%, P < 0.001, I2 7%, P = 0.37). All 
studies in this sub-group were of 6 months or less duration, or only reported outcomes at 6 
months.  
 
Baseline HbA1c amongst the study groups ranged from 43mmol/mol (6.1%) to 87 mmol/mol 
(10.1%), with some studies specifically excluding participants with poorly-controlled blood 
glucose and others adopting the opposite strategy.  
 
Body Weight 
Changes in body weight or Body Mass Index (BMI) were included in the majority of studies, 
however body weight outcomes were not available for two studies which were therefore 
excluded from the meta-analysis.26,27 Two studies38,43 reported a sample with near healthy 
weight and BMI at baseline. Significant between-group differences in body weight were 
observed in just 5 of the 25 included studies, 3 of which were from the sub group of LCHDs. 
There was no overall effect in the meta-analyses for weight for all studies (WMD -0.13kg, 
95% CI -0.33kg, 0.08kg, P = 0.22, I2 78%, P <0.001) (Figure 3 – supplementary material). A 
high level of heterogeneity was seen in the pooled meta-analysis but not in the low 
carbohydrate sub group. This sub group showed a statistically significant pooled effect in 
favour of restricted carbohydrate (WMD -0.43kg, 95% CI -0.74kg, -0.12kg, P = 0.006, I2 24%, 
P = 0.26).  
 Blood Pressure & Blood Lipids 
Of the 25 studies, 11 did not fully report outcomes for BP and in those that did, changes 
were unremarkable and rarely reached statistical significance. Such differences between 
groups were seen only in the paper by Jonsson et al.36 
 
Complete blood lipid outcomes were reported in 17 of the 25 studies. Statistically significant 
differences between groups were seen in just 7 of the studies and most commonly observed 
difference was a greater increase in HDL-Cholesterol in the modified carbohydrate group.  
 
Study Diets, dietary assessment & adherence 
The amount of carbohydrate participants were instructed to consume within the 
‘moderate+’ group ranged from 138g per day to 293g per day (or 194g if the two ‘high’ 
carbohydrate studies are excluded). Half the studies included in this review did not report or 
record the baseline carbohydrate intake of participants. Several trials in the moderate group 
described the interventions as ‘low carbohydrate’ at a prescribed level based on 40% of 
total energy intake. Adherence to study diets was observed more frequently in the 
moderate+ group than in other groups. 
 
13 studies demonstrated relative adherence to the prescribed carbohydrate intake in the 
intervention arm (+/- 10% in g carbohydrate). A further sub-group analysis of the effect on 
the primary outcome using only these studies showed no impact on overall carbohydrate 
restriction (WMD –0.06 95% CI -0.15, 0.02, P = 0.16, I2 88%, P < 0.01) (Figure 4 – 
supplementary material). Of these 13 studies, 10 were within the ‘Moderate+’ group of 
carbohydrate restriction, 2 were ‘Low Carbohydrate’ and 1 from the ‘Very Low 
Carbohydrate’ group. The mean average carbohydrate intake in the intervention group of 
the 13 studies was 150g (range 41-209g, median 166g) and the control diets were mostly 
low fat, high carbohydrate in this group.  
 
A variety of methods for dietary measurement were used by the individual studies, ranging 
from a 24-hour recall, food frequency questionnaires or 7-day weighed food records to 
smartphone apps such as MyFitnessPal. Several studies did not describe how dietary 
assessment was carried-out.32,38,44  
 
Discussion 
This systematic review and meta-analysis of carbohydrate restriction for glycaemic control 
in Type 2 DM has shown no significant overall effect on HbA1c or body weight. Current 
national nutrition guidelines for Type 2 DM reflect this and do not make a specific 
recommendation about the quantity of carbohydrate.6–8   
 
A small and clinically-significant reduction of 5mmol/mol (0.48%) in HbA1c was seen in the 
sub-group of studies using 50-130g of carbohydrate per day. These studies were 6 months 
or less in duration, or only reported outcomes at 6 months, an important limitation to the 
clinical application of this finding.  Earlier reviews found that reductions in HbA1c or weight 
at 3 or 6 months are not maintained beyond 12 months.11,13–15 Adherence to the prescribed 
diets in this group was good and may be an important factor in the positive result seen in 
the meta-analysis, but if this success cannot be replicated in longer trials, or using even 
greater restrictions in carbohydrate, then this is an important finding with implications for 
future research and clinical practice.  
 
Findings in the context of existing evidence 
Eight other meta-analyses published in the last 5 years address a similar research question 
to the current review and their findings are summarized in Table 5. The lack of agreement 
amongst them is due in part to differences in the methodology, such as the inclusion criteria 
or the approach taken in meta-analysis. Several reviews had similar findings to the present 
review13,15,45 and Snorgaard et al13 also found the greatest improvements in HbA1c were 
associated with the greatest reductions in carbohydrate, a finding which is not replicated in 
the present review.  
 
Strengths & limitations of underlying studies 
Several methodological limitations are present in the studies included in this review, 
specifically the lack of isocaloric study arms, the varied methods of dietary assessment, 
differences in baseline glycaemic control of study participants, a lack of concordance with 
the study diet, and differences in study protocols for adjustment of diabetes medication.  
 
Improvements in HbA1c are regularly seen in both groups in included studies and may be 
related to a reduction in energy intake and subsequent weight loss across the entire study 
population. With some exceptions,24,34,35 most studies did not intend to keep the amount of 
dietary energy between study arms equal, and therefore results may have been confounded 
by differential changes in weight as a result of differing energy intakes between study 
groups. Caution should be exercised in interpreting these outcomes in the context of dietary 
changes, especially given the heterogeneity in the methods of dietary measurement 
employed, and their inherent inaccuracy. 
 
Only 13 of the studies included in this review demonstrated overall concordance with the 
prescribed quantity of carbohydrate, and in several cases where there was concordance, the 
quantity of carbohydrate consumed was very similar to the pre-study or baseline intake.46–49 
Although in each case there was a small reduction in carbohydrate intake in the intervention 
group, it could be questioned whether these studies did achieve what they intended and 
therefore the validity of including them in this meta-analysis. The differences between the 
intervention and control diets often amounted to far more than a simple difference in the 
quantity of carbohydrate consumed. The nature of adjusting either the absolute amount or 
proportion of one nutrient automatically means either the proportion or absolute amount 
of other macronutrients will also be altered. In fact, this was sometimes the primary aim of 
the study.36,49,50 The results of the present review are consistent with the findings from van 
Wyk et al10, who concluded both low carbohydrate and high carbohydrate groups have 
difficulty in achieving and adhering to the prescribed level of carbohydrate intake, with a 
difference between groups as small as 8g per day. Most trials used an intention-to-treat 
approach to the analysis, however none of the studies included in the present review 
performed additional analysis only on participants adhering to the protocol diet. 
 
A wide range of methods of dietary assessment were used across the studies included in 
this review. Despite almost all trials employing a dietitian to advise participants and 
administer the monitoring of dietary intake, there are inherent inaccuracies in whichever 
method is chosen, and comparison between methods has long been recognized as 
troublesome.51,52  If randomization had left significant differences between study arms with 
respect to the pre-study habitual dietary intake, this would have to be acknowledged as a 
potential risk of bias, however many of the included studies failed to measure or report the 
composition of participants’ diets prior to commencement of the trial. 36,38,40,44,50,53,54   
 
Other limitations include the wide range of baseline HbA1c values and adjustment of anti-
hyperglycaemic medication. Participants with poorly-controlled blood glucose were part of 
the exclusion criteria in several studies, however this may not be representative of a typical 
clinical population. Many studies used a protocol to adjust medication according to blood 
glucose during the trial, whilst others excluded patients based on their diabetes medication. 
Investigators either advised participants to undertake a recommended amount of physical 
activity each day or to continue with their usual activities, but the majority did not report or 
adjust for physical activity level in the analysis, which could be a significant limitation.  
 
RCTs of dietary interventions are notoriously challenging with regards to minimising bias, 
although numerous strategies have been recommended.55 Blinding of treatment allocation 
to patients and those delivering the intervention is rarely possible, and the nature of dietary 
interventions involving complex lifestyle and behaviour changes means participants are 
likely to have a strong preference, which may in turn affect adherence and attrition. Subject 
bias and the Hawthorne effect are also likely in dietary intervention trials and may be 
evident in studies in this review, such as Jonasson et al34 in which participants were 
informed of the diet allocation prior to assessment of baseline nutritional intake. Most 
studies did not sufficiently report their efforts to minimize bias and could have described 
how blinding of outcome assessment and the personnel involved in data handling, for 
instance, might contribute to minimizing bias.  
 
Strengths of this review 
This review provides an updated evaluation of research to establish the impact of 
carbohydrate restriction on glycaemic control in Type 2 DM and examines the potential 
impact of dietary adherence on the primary outcome, which previous reviews failed to fully 
address. Other systematic reviews and meta-analyses include database searches up to July 
201756 and did not include a recent study57 which has been included in this review. Two 
reviews also looked specifically at low carbohydrate vs. low fat rather than a range of 
control diets as in this review,56,58 and the review by Sainsbury et al15 included studies with 
participants with Type 1 DM. Therefore, the added value of this review is the sub-group 
analysis of the 13 studies demonstrating relative adherence to the intervention diet. This 
aimed to address questions regarding the role of adherence in the primary outcome, 
however may have been confounded by the proportion of studies in the moderate+ group 
which formed part of this sub-group. 
 
The standardisation of definitions relating to the level of carbohydrate intake is an 
important consideration. This review categorised studies according to the proposed levels 
by Acurso59 and Feinman et al29, which means some individual studies were re-categorised 
from their stated level of restriction to match these level descriptors. For example, studies 
often used ≤40% of total energy to define ‘low carbohydrate’, however this is now accepted 
as ‘moderate carbohydrate’. The rationale for selecting this level of restriction is rarely 
explicated and it is likely that this merely represents an intake that is less than the habitual 
intake of western populations.60,61 However, it is much higher than levels likely to result in 
short-term improvements in glycaemic control, as demonstrated in this review, and led to 
participants consuming levels of carbohydrate not dissimilar from their pre-study 
consumption.  
 
Limitations of this review  
The inclusion criteria for this review was intended to encompass the breadth of evidence 
regarding levels of carbohydrate in Type 2 DM however the large variation in the duration of 
included trials, the range of dietary approaches employed and whether included studies 
achieved the intended dietary changes may also limit the findings. Sub-group analysis 
suggests that including only studies lasting 12 months or more would not have any material 
impact on the overall pooled effect, a finding supported by other reviews that have grouped 
their analyses by study duration.15,62 The exclusion of trials that did not report the 
carbohydrate intake of participants is recognised as a potential source of bias, however this 
resulted in the exclusion of only one RCT63 and most trials were excluded due to their 
duration or non-reporting of the primary outcome (HbA1c).   
 The meta-analysis for HbA1c includes a sub-group of trials of moderate carbohydrate in 
which a high level of heterogeneity is observed (I2 82%, p<0.001). A wide range of different 
dietary approaches are employed in this group, which may confound the ability to draw 
conclusions from the pooled effect.  
 
The present review did not undertake a meta-regression to assess the effects of other 
variables on the primary outcome of HbA1c, such as changes in diabetes medication, 
physical activity or weight. Many of the studies did not report on medication changes or 
physical activity, so this remains a potential unobserved confounder. Weight loss is 
recognised as a significant predictor of improvements in glycaemic control in Type 2 DM and 
the network meta-analysis by Schwingschackl et al56 demonstrated a significant relationship 
between reduction in HbA1c and mean differences in weight. However, meta-regression is 
not always appropriate where there are fewer than 10 studies in a sub-group18 as is the case 
for two of the sub-groups included in this meta-analysis. 
 
Conclusion  
This review provides evidence of short term improvements in glycaemic control from a 
restriction in carbohydrate intake to 50-130g per day, however it suggests there is little 
evidence to support recommending a general restriction of carbohydrate intake for all 
patients with Type 2 DM. Controversy in the area of dietary carbohydrate will likely persist, 
with recent publications such as the PURE study calling for dietary guidelines to be 
reconsidered.64 However, data from studies of carbohydrate-restricted diets raises 
important questions over the long-term sustainability of such diets, given the poor overall 
concordance with the prescribed quantity of carbohydrate, even in a trial setting.  As 
suggested by Van Wyk et al10, it is likely there is significant variation in glycaemic response 
to carbohydrate between patients, which may explain the inconclusive nature of trials. 
Future research should consider the acceptability of carbohydrate-restricted diets and how 
to identify patients who will benefit most from being offered this approach. Researchers 
planning trials in this field should consider carefully the added value of further RCTs, given 
the number of systematic reviews already published. In order to add value, any future trials 
should be long-term (greater than 12 months), adopt the prevailing definitions of low 
carbohydrate and intend to keep both the caloric content of the diets in study arms, and 
any changes in body weight, equal. Current guidelines should reflect the short-term 
improvements in glycaemic control that diets restricted to 50-130g of carbohydrate per day 
can offer as the evidence-based approach in Type 2 DM.  
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Systematic Review Search Strategy (Ovid: Medline & Embase) 
Type 2 Diabetes Mellitus 
1. exp Diabetes Mellitus, Type 2/ 
2. (MODY or NIDDM or T2DM).tw,ot. 
3. (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non 
insulin?depend).tw,ot. 
4. ((typ$ 2 or typ$ II) adj3 diabet$).tw,ot. 
5. (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).ab,ti.  
6. Or/1-5  
Diet & Carbohydrate Interventions  
7. explode Diet Therapy/ [MeSH, all subheadings] 
8. (diet$ adj5 diabet$).ab,ti. 
9. (diet$ adj5 carbohydrat$).ab,ti. 
10. (diet$ adj5 sugar$).ab.ti 
11. 7 or 8 or 9 or 10 
Randomised Controlled Trials 
12. randomized controlled trial.pt. 
13. controlled clinical trial.pt 
14. randomi?ed.ab,ti. 
15. randomly.ab,ti 
16. trial$.ab,ti. 
17. Or/12-16 
Systematic Reviews / Meta-Analysis  
18. meta-analysis.pt 
19. exp Meta-Analysis/ 
20. (meta analy$ or metaanaly$ or meta?analy$).tw,ot. 
21. Or/18-20 
Type 2 Diabetes and All Interventions 
22. 6 and 11 
Type 2 Diabetes and All Interventions and Randomised Controlled Trial 
23. 22 and 17 
Type 2 Diabetes and All Interventions and Systematic Reviews / Meta-Analysis  
24. 22 and 21 
 
 
 
